A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
An article from
Dive Brief
//
Obesity drugs
A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.
GLP-1 battle heats up again as Novo claws its way back into race with Lilly
Novo vs. Lilly: Q2's cardiometabolic grudge match
Novo Dives On A Key Miss As Its Battle With Lilly Heats Up
Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom
Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
Weight Loss Drug Titans Slump Below Key Levels. This Is Why.
The two pharmaceutical giants are locked in a fierce battle for dominance in the burgeoning obesity drug market
Novo Nordisk and Eli Lilly are reporting Q2 earnings this week, as Novo's Wegovy pill outsells Lilly's Foundayo and a dealmaking…
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and…
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.
In Novo Nordisk and Eli Lilly’s competition to launch their respective GLP-1 obesity pills in the United States, the Danish…
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
